Children With High Risk For A Sleep-Related Breathing Disorder Are More Likely To Have Anxiety

Children with high risk for a sleep-related breathing disorder (SRBD) are more likely to have anxiety, according to a research abstract presented on Monday at SLEEP 2008, the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS).

Results From One-Year Study Suggest Advair R Provides Important Benefits For African American Patients With Asthma

African American patients with asthma treated with Advair Diskus, a combination of the long-acting beta-agonist (LABA) salmeterol and the inhaled corticosteroid (ICS) fluticasone propionate, had a lower rate of exacerbations when compared with patients who received treatment with the ICS Flovent Diskus(R) (fluticasone propionate inhalation powder) alone, although the difference was not statistically significant.

African-American Veterans Are Less Likely To Adhere To CPAP Than Caucasian Or Asian Veterans

African-American war veterans are significantly less likely to adhere to continuous positive airway pressure (CPAP) than Caucasian or Asian veterans, according to a research abstract presented on Monday at SLEEP 2008, the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS).

A Global Report On Care Of Non-communicable Diseases In Sub Saharan Africa By The Union And Its Partners To Be Published By The PLoS

The International Union Against Tuberculosis and Lung Disease (The Union), an international organisation established in 1920 to fight tuberculosis and promote lung health worldwide, has prepared a report, published in PLoS Medicine by the Public Library of Science (PLoS), on managing diabetes, asthma, high blood pressure, epilepsy and other non-communicable diseases in sub-Saharan Africa that will provide lessons for treating patients worldwide.

Health Experts Call On Global Leaders To Ensure Access To Life-Saving Pneumococcal Vaccines

Nearly 1, 000 of the world's leading experts in infectious diseases and vaccines are meeting during the 6th International Symposium on Pneumococci and Pneumococcal Diseases (ISPPD-6) this week to call for renewed and urgent action by governments to protect their citizens against pneumococcal disease, a leading killer of children and adults worldwide.

OSA Patients Better Educated From Sleep Medicine Specialists, Accredited Sleep Centers

Obstructive sleep apnea (OSA) patients cared for by sleep centers accredited by the American Academy of Sleep Medicine (AASM) and certified sleep medicine specialists receive better education than patients cared for by non-AASM accredited centers and non-certified physicians, according to a research abstract presented on Tuesday at SLEEP 2008, the 22nd Annual Meeting of the Associated Professional Sleep Societies (APSS).

Aradigm Initiates Phase 2 Study Of Inhaled Liposomal Ciprofloxacin In Bronchiectasis

Aradigm Corporation (OTCBB: ARDM) announced it has initiated a multicenter Phase 2 clinical trial of its inhaled liposomal ciprofloxacin in adult patients with non-cystic fibrosis bronchiectasis. Following an antibiotic washout period, 36 patients will be enrolled to receive daily inhaled liposomal ciprofloxacin for a period of 28 consecutive days.

FDA Approves Diaphragm-Pacing Device

The U.S. Food and Drug Administration announced that it approved the NeuRx DPS RA/4 Respiratory Stimulation System, an implantable electronic device that stimulates the diaphragm and allows certain spinal cord injury patients to breathe for at least four hours a day without a mechanical ventilator.

Significant Improvement In Asthma And Osteoarthritis After Bariatric Surgery - Most No Longer Require Steroids Within 18 Months

Most patients with asthma and osteoarthritis were able to stop taking steroids within 18 months of bariatric surgery, according to a new study presented here at the 25th Annual Meeting of the American Society for Metabolic & Bariatric Surgery (ASMBS).

Grazax R Demonstrates Significant Reductions On Asthma Symptoms In Children

In Addition to Effects on Allergic Rhinitis (Hayfever), GRAZAX(R)Demonstrated Significant Reductions in Asthma Symptoms in Children Aged 5 to16 Years Old. ALK-Abell~A^3 today presented successful results from a new clinical trial, GT-12, designed to measure the impact of GRAZAX(R) on allergic rhinitis andallergic asthma.